Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)
Kalinsky, Kevin, Barlow, William E, Meric-Bernstam, Funda, Gralow, Julie R, Albain, Kathy S, Hayes, Daniel, Lin, Nancy, Perez, Edith A, Goldstein, Lori J, Chia, Stephen, Dhesy-Thind, Subkhbinder, Rastogi, Priya, Alba, Emilio, Delaloge, Suzette, Martín, Miguel, Gil, Miguel Gil, Arce-Salinas, Claudia, Brain, Etienne, Park, In Hae, Pierga, Jean-Yves, Lluch, Ana Hernandez, Vasquez, Manuel Ramos, Borrego, Manuel Ruiz, Jung, Kyung Hae, Ferrero, Jean-Marc, Schott, Anne, Shak, Steve, Sharma, Priyanka, Lew, Danika L, Miao, Jieling, Tripathy, Debu, Hortobagyi, Gabriel, Pusztai, Lajos
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article